TARS - Tarsus Pharmaceuticals EPS misses by $0.42 misses on revenue
Tarsus Pharmaceuticals (NASDAQ:TARS): Q3 GAAP EPS of -$0.76 misses by $0.42. Revenue of $1.24M misses by $4.09M. Press Release Cash and equivalents of $184M as of September 30, 2021, for expected runway into the second half of 2023.
For further details see:
Tarsus Pharmaceuticals EPS misses by $0.42, misses on revenue